회원학회

회원학회

번호 연구제목 연구자 연구기간 발표실적
내용
28 소시호탕 투여를 통해 호전된 항문직장암 환자의 수술부위 감염 이후 발생한 신경병성 통증 1례 김준열, 서현식, 주한음, 박정향, 박지혜, 조정효, 유화승 2023-01 ~ 학회지
Objectives: To demonstrate an improvement of neuropathic pain after surgical site infection in a patient with anorectal cancer by administration of Soshihotang (SSHT).
Methods: A 65-year-old female patient diagnosed with anorectal cancer was administered SSHT to
relieve her neuropathic pain induced by surgical site infection. SSHT was administered from
4/22 to 5/2. Clinical outcomes were assessed using a numeric rating scale (NRS), and opioids
administered to relieve her pain was calculated.
Results: During 10 days of treatment, the NRS scale of neuropathic pain was improved and the
dosage of opioids administered reduced to less than half.
Conclusions: This case suggests that SSHT could be effective for the management of neuropathic
pain induced by surgical site infection.
27 유방암 환자의 통함 암 치료를 통한 항암화학요법 유발 말초신경병증, 전신통 호전에 대한 증례 보고 김은지, 배혜리, 이남헌 2023-01 ~ 학회지
Objectives: To report the improvement of chemotherapy-induced peripheral neuropathy and pantalgia
with integrative cancer treatment on adverse effects of chemotherapy in a breast cancer patient.
Methods: A 63-year-old female patient who has been diagnosed with breast cancer got treated for
103 days with integrative cancer treatment including acupuncture, moxibustion, herbal medicine,
physiotherapies, hand and foot bath to decrease side effects of chemotherapy. The patient was also treated Western immunotherapies like Thymosin, Viscum album. Paclitaxel, Carboplatin,
Doxorubicin, Cyclophosphamide was applied and chemotherapy-induced peripheral
neuropathy(CIPN), pantalgia and nausea occured. The efficacy of treatment was measured by a numeric rating scale(NRS) of symptoms, National Cancer Institute Common Terminology Criteria
for Adverse Event(NCI-CTCAE) and Eastern Cooperative Oncology Group(ECOG) Performance
Status Scale.
Results: The NRS scroes for CIPN, pantalgia, nausea were improved. There was no adverse effects
of 3 or higher assessed by the NCI-CTCAE. The ECOG grade improved from grade 2 to 1.
Conclusions: This study suggests that integrative cancer treatment could improve CIPN, pantalgia
after chemotherapy in breast cancer.
26 탁리소독음 단독치료로 호전된 유방암 수술부위감염 1례 윤성수, 하수정, 정문수, 윤성우 2023-01 ~ 학회지
Objectives: With antibiotic resistance one of the biggest threats to global health, we report a case of surgical site infection (SSI) after breast cancer surgery that improved only with the treatment
of Taglisodog-eum (托裏消毒飮), Korean herbal medicine, without the use of antibiotics.
Methods: The patient diagnosed with ductal carcinoma in situ of left breast underwent nipple
areola skin sparing mastectomy and reconstruction using deep inferior epigastric perforator flap.
About a month later, superficial SSI occurred at the incision site of breast cancer surgery with
general weakness, and Taglisodog-eum treatment was started. To evaluate the effectiveness of the
treatment, we compared the infection site conditions before and after treatment.
Results: About three weeks after taking Taglisodog-eum, the SSI improved along with the
improvement of general weakness.
Conclusions: This study shows that Taglisodog-eum may be effective for SSI after breast cancer surgery, and the potential for alternatives to reduce antibiotic use and antibiotic resistance.
25 Effects of combined acupuncture and gabapentin treatment on chemotherapy-induced peripheral neuropathy: a pilot, randomized, assessor-blinded, controlled trial Hyun Jung Jung, Dae Jun Kim, Joon Seok Byun 2023-01 ~ 학회지
목적: 항암유발말초신경병증은 암 환자가 겪는 흔한 항암 부작용이나 현재까지 효과적으로 알려진
치료법은 없다. 본 연구의 목적은 항암유발말초신경병증에 대한 침 치료와 가바펜틴의 병용 요법
의 효과와 안전성을 평가하는 것이다. 방법: 항암유발말초신경병증을 겪고 있는 24명의 암 환자를 침 치료 단독군 (AG, acupuncture group)과
침과 가바펜틴의 병용요법군 (CG, combined acupuncture and gabapentin group)으로 무작위 배정하였다. 두 그룹 모두 침 치료는 주 3회, 4주간 수행하였다. 병용 요법군은 침 치료와 더불어 1일 900mg의 가
바펜틴을 복용하도록 하였다. 치료 효과는 Neuropathic Pain Symptom Inventory (NPSI), visual analogue
scale (VAS), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–
Chemotherapy-Induced Peripheral Neuropathy 20 items (EORTC-CIPN20)를 이용하여 측정하였다. 치료로
인한 부작용은 대상자가 방문할 때마다 조사하였다. 결과: 총 23명의 대상자(AG, n=12; CG, n=11)의 평가지표를 분석한 결과, 치료 4 주 후 침 치료 단
독군은 NPSI 점수가 44.33±25.04에서 30.58±21.55으로 감소하였고, 병용 요법군은 30.55±25.59에
서 18.64±19.42로 감소하였으며, 두 군 모두 통계적으로 유의미하게 감소하였다(p<0.001). VAS점
수는 침 치료 단독군에서는 4.79±2.17 에서 3.42±2.49으로 감소하였고, 병용 요법군에서는
3.55±2.07에서 2.73±2.49 로 감소하였다(p<0.05). 치료 효과는 치료 완료 2주후까지 지속되었으
며, 두 군간의 유의미한 차이는 없었다. EORTC-CIPN20은 침 치료 단독군은 30.27±18.87에서
20.84±16.35으로 감소하여(p<0.01), 두 군 모두에서 삶의 질이 향상되었다. 결론: 본 연구로 침 치료와 가바펜틴의 병용 요법이 항암유발말초신경병증 환자의 증상 및 삶의 질
개선에 효과적이며 안전한 치료법임을 확인하였다. 그러나 침 치료와 가바펜틴의 시너지 효과에
대해서는 확인 할 수 없었으며, 이를 확인하기 위해 추가적인 연구가 필요할 것으로 사료된다.